{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:45:57Z","timestamp":1778593557444,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.idnow.2025.105125","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:18Z","timestamp":1753891278000},"page":"105125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Duration of antibiotic treatment for community-acquired pneumonia"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-4819","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Dinh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-831X","authenticated-orcid":false,"given":"David","family":"Lebeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105125_b0005","series-title":"Serum Therapy","first-page":"283","author":"Bullowa","year":"1937"},{"key":"10.1016\/j.idnow.2025.105125_b0010","first-page":"142","article-title":"The Treatment of Lobar pneumonia and pneumococcal empyema with penicillin","volume":"20","author":"Tillett","year":"1944","journal-title":"Bull NY Acad Med"},{"key":"10.1016\/j.idnow.2025.105125_b0015","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jama.1943.02840350001001","article-title":"Penicillin in the treatment of infections","volume":"122","author":"Keefer","year":"1943","journal-title":"J Am Med Ass"},{"key":"10.1016\/j.idnow.2025.105125_b0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.1944.02850100001001","article-title":"The clinical use of Penicillin","volume":"124","author":"Dawson","year":"1944","journal-title":"J Am Med Ass (JAMA)"},{"key":"10.1016\/j.idnow.2025.105125_b0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/thx.25.2.241","article-title":"One-day treatment for lobar pneumonia","volume":"25","author":"Sutton","year":"1970","journal-title":"Thorax"},{"key":"10.1016\/j.idnow.2025.105125_b0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJM194506282322601","article-title":"Treatment of Pneumococcal Pneumonia with Penicillin","volume":"232","author":"Meads","year":"1945","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.idnow.2025.105125_b0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)17907-0","article-title":"ESAC Project Group. outpatient antibiotic use in Europe and association with resistance: a cross-national database study","volume":"365","author":"Goossens","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2025.105125_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/28.suppl_C.31","article-title":"A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe","volume":"28","author":"Baquero","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2025.105125_b0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.279.5.365","article-title":"Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae","volume":"279","author":"Guillemot","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2025.105125_b0050","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2025.105125_b0055","doi-asserted-by":"crossref","unstructured":"Infectious Diseases Society of America (IDSA). Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. Clinical Infectious Diseases. 2011;52:S397\u2013428. Doi: 10.1093\/cid\/cir153.","DOI":"10.1093\/cid\/cir153"},{"key":"10.1016\/j.idnow.2025.105125_b0060","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of adults with Community-acquired Pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of america","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.idnow.2025.105125_b0065","unstructured":"National Institute for Health and Care Excellence [Internet]. 2019. Pneumonia (community-acquired): antimicrobial prescribing [cited January 15, 2020]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng138."},{"key":"10.1016\/j.idnow.2025.105125_b0070","doi-asserted-by":"crossref","unstructured":"Chidiac C; Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise; Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale dans les infections respiratoires basses de l'adulte. Pneumonie aigu\u00eb communautaire. Exacerbations de bronchopneumopathie chronique obstructive [Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis]. Med Mal Infect. 2011;41(5):221-8. French. Doi: 10.1016\/j.medmal.2010.10.001.","DOI":"10.1016\/j.medmal.2010.10.001"},{"key":"10.1016\/j.idnow.2025.105125_b0075","doi-asserted-by":"crossref","unstructured":"Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, Group TCCW. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000;11:237\u201348. Doi: 10.1155\/2000\/457147.","DOI":"10.1155\/2000\/457147"},{"key":"10.1016\/j.idnow.2025.105125_b0080","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the Management of Adults with Community-acquired Pneumonia","volume":"163","author":"Niederman","year":"2001","journal-title":"Ame J Respir Crit Care Med"},{"key":"10.1016\/j.idnow.2025.105125_b0085","doi-asserted-by":"crossref","unstructured":"British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56 Suppl 4:IV1-64. Doi: 10.1136\/thorax.56.suppl_4.iv1.","DOI":"10.1136\/thx.56.suppl_4.iv1"},{"key":"10.1016\/j.idnow.2025.105125_b0090","doi-asserted-by":"crossref","unstructured":"American Thoracic Society; Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med. 2005;171:388\u2013416. Doi: 10.1164\/rccm.200405-644ST.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"10.1016\/j.idnow.2025.105125_b0095","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1183\/09031936.05.00055705","article-title":"Guidelines for the management of adult lower respiratory tract infections","volume":"26","author":"Woodhead","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.idnow.2025.105125_b0100","doi-asserted-by":"crossref","unstructured":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise. XVe Conf\u00e9rence de consensus en th\u00e9rapeutique anti-infectieuse. Prise en charge des infections des voies respiratoires bassesde l'adulte immunocomp\u00e9tent [15th consensus conference about management of lower respiratory tract infections in immunocompetent adult]. Med Mal Infect. 2006;36(5):235-44. French. Doi: 10.1016\/j.medmal.2006.04.003.","DOI":"10.1016\/j.medmal.2006.04.003"},{"issue":"Suppl 2","key":"10.1016\/j.idnow.2025.105125_b0105","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America (IDSA)\/American Thoracic Society (ATS) consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0110","doi-asserted-by":"crossref","unstructured":"Chidiac C; Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise; Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale dans les infections respiratoires basses de l'adulte. Pneumonie aigu\u00eb communautaire. Exacerbations de bronchopneumopathie chronique obstructive [Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis]. Med Mal Infect. 2011;41(5):221-8. French. Doi: 10.1016\/j.medmal.2010.10.001.","DOI":"10.1016\/j.medmal.2010.10.001"},{"key":"10.1016\/j.idnow.2025.105125_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections - Summary","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.idnow.2025.105125_b0120","first-page":"4","article-title":"Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT)","volume":"76","author":"Wiersinga","year":"2018","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.idnow.2025.105125_b0125","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/cid\/cix986","article-title":"Duration of Antibiotic Use among adults with Uncomplicated Community-acquired Pneumonia Requiring Hospitalization in the United States","volume":"66","author":"Yi","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M18-3640","article-title":"Excess Antibiotic Treatment Duration and adverse events in patients Hospitalized with Pneumonia","volume":"171","author":"Vaughn","year":"2019","journal-title":"Ann of Intern Med"},{"issue":"11","key":"10.1016\/j.idnow.2025.105125_b0135","doi-asserted-by":"crossref","first-page":"e4499","DOI":"10.1093\/cid\/ciaa1372","article-title":"Antibiotic Overuse after Hospital Discharge: a Multi-hospital Cohort Study","volume":"73","author":"Vaughn","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0140","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2217\/fmb.15.40","article-title":"Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance","volume":"10","author":"de Lastours","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.idnow.2025.105125_b0145","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/jac\/dkx043","article-title":"Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers","volume":"72","author":"de Lastours","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2025.105125_b0150","first-page":"837","article-title":"Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. American J Respir","volume":"162","author":"Gruson","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.idnow.2025.105125_b0155","doi-asserted-by":"crossref","unstructured":"Paup\u00e9rio F, Ganusov V, Gjini E. Mathematical modeling links benefits of short and long antibiotic treatment to details of infection. bioRxiv. 2019:555334. Doi: 10.1101\/555334.","DOI":"10.1101\/555334"},{"key":"10.1016\/j.idnow.2025.105125_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029838","article-title":"\u201cOne-Size-Fits-all\u201d? Optimizing Treatment Duration for Bacterial Infections","volume":"7","author":"Geli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.idnow.2025.105125_b0165","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtbi.2007.08.011","article-title":"Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration","volume":"249","author":"D\u2019Agata","year":"2007","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.idnow.2025.105125_b0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. a proposed solution for indiscriminate antibiotic prescription","volume":"162","author":"Singh","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.idnow.2025.105125_b0175","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1086\/504483","article-title":"Use of Quantitative Cultures and Reduced Duration of Antibiotic Regimens for patients with Ventilator-Associated Pneumonia to Decrease Resistance in the Intensive Care Unit","volume":"43","author":"Chastre","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00134-002-1565-2","article-title":"Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs","volume":"29","author":"Geissler","year":"2003","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.idnow.2025.105125_b0185","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.medmal.2006.07.012","article-title":"Impact d\u2019une politique de prescription d\u2019antibiotiques dans un service de r\u00e9animation tunisien","volume":"36","author":"Brahmi","year":"2006","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.idnow.2025.105125_b0190","doi-asserted-by":"crossref","unstructured":"Paterson DL. The Role of Antimicrobial Management Programs in Optimizing Antibiotic Prescribing within Hospitals. Clin Infect Dis. 2006;42:S90\u20135. Doi: 10.1086\/499407.","DOI":"10.1086\/499407"},{"key":"10.1016\/j.idnow.2025.105125_b0195","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? the DTP randomized trial","volume":"36","author":"Dinh","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0200","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2025.105125_b0205","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamasurg.2019.0569","article-title":"Association of Duration and Type of Surgical Prophylaxis with Antimicrobial-Associated adverse events","volume":"154","author":"Branch-Elliman","year":"2019","journal-title":"JAMA Surg."},{"key":"10.1016\/j.idnow.2025.105125_b0210","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","article-title":"Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone","volume":"175","author":"Lee","year":"2015","journal-title":"JAMA Internal Med"},{"issue":"4","key":"10.1016\/j.idnow.2025.105125_b0215","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1462-5822.2010.01428.x","article-title":"Tracking the dynamic interplay between bacterial and host factors during pathogen-induced vacuole rupture in real time","volume":"12","author":"Ray","year":"2010","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.idnow.2025.105125_b0220","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.1522510113","article-title":"Bacteroides fragilis type VI secretion systems use novel effector and immunity proteins to antagonize human gut Bacteroidales species","volume":"113","author":"Chatzidaki-Livanis","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.idnow.2025.105125_b0225","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/cix947","article-title":"Risk of subsequent Sepsis within 90 days after a Hospital Stay by Type of Antibiotic Exposure","volume":"66","author":"Baggs","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0230","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1183\/09031936.03.00026103","article-title":"Duration of length of stay in pneumonia: Influence of clinical factors and hospital type","volume":"22","author":"Men\u00e9ndez","year":"2003","journal-title":"Eur Respirar J"},{"key":"10.1016\/j.idnow.2025.105125_b0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2466-12-21","article-title":"Predictors for length of hospital stay in patients with community-acquired Pneumonia: results from a Swiss Multicenter study","volume":"12","author":"Suter-Widmer","year":"2012","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.idnow.2025.105125_b0240","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.idnow.2025.105125_b0245","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1183\/09031936.00105513","article-title":"Respiratory health and disease in Europe: the new European Lung White Book","volume":"42","author":"Gibson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.idnow.2025.105125_b0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.idnow.2025.105125_b0255","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.amjmed.2007.04.023","article-title":"Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis","volume":"120","author":"Li","year":"2007","journal-title":"Ame J Med"},{"key":"10.1016\/j.idnow.2025.105125_b0260","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of adults with Mild to Moderate Community-acquired Pneumonia","volume":"17","author":"O\u2019Doherty","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0265","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2004.01.011","article-title":"Azithromycin versus comparative therapy for the treatment of community acquired pneumonia","volume":"24","author":"Rahav","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2025.105125_b0270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0275","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.95.08030398","article-title":"Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia","volume":"8","author":"Rizzato","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.idnow.2025.105125_b0280","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3109\/00365549409008639","article-title":"Three-day Azithromycin Compared with Ten-day Roxithromycin Treatment of Atypical Pneumonia","volume":"26","author":"Sch\u00f6nwald","year":"1994","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0285","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0399-077X(02)00384-0","article-title":"Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors","volume":"32","author":"L\u00e9ophonte","year":"2002","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.idnow.2025.105125_b0290","first-page":"757","article-title":"Clarithromycin-controlled randomized double-blind studies of azithromycin for treatment of pneumonia","volume":"43","author":"Kobayashi","year":"1995","journal-title":"Japanese Journal of Chemotherapy"},{"key":"10.1016\/j.idnow.2025.105125_b0295","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/25.suppl_A.123","article-title":"Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias","volume":"25","author":"Schonwald","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2025.105125_b0300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1179\/joc.2004.16.1.102","article-title":"Comparative Study of the Efficacy and Tolerance of azithromycin versus clarithromycin in the treatment of community- acquired pneumonia in adults","volume":"16","author":"Sopena","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.idnow.2025.105125_b0305","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0310","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"L\u00e9ophonte","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.idnow.2025.105125_b0315","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2025.105125_b0320","doi-asserted-by":"crossref","unstructured":"Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother. 2018;62:pii:e00635-18. Doi: 10.1128\/AAC.00635-18.","DOI":"10.1128\/AAC.00635-18"},{"key":"10.1016\/j.idnow.2025.105125_b0325","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2165\/00003495-200868130-00004","article-title":"Short- versus Long-Course antibacterial therapy for community-acquired pneumonia","volume":"68","author":"Dimopoulos","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.idnow.2025.105125_b0330","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12879-018-3515-9","article-title":"High heterogeneity in community-acquired pneumonia inclusion criteria: does this impact on the validity of the results of randomized controlled trials?","volume":"18","author":"Flateau","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.idnow.2025.105125_b0335","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired Pneumonia","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.idnow.2025.105125_b0340","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.idnow.2025.105125_b0345","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2025.105125_b0350","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T02:35:32Z","timestamp":1756953332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925001046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666991925001046"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105125","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of antibiotic treatment for community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105125"}}